The U.S. Food and Drug Administration released final guidance on October 20, 2026, outlining how drug companies should develop, distribute, and label prescription drug apps used alongside their medicines. The framework addresses when app content falls under FDA submission requirements, when software should be mentioned in official prescribing information, and what companies should submit to the agency.
For patients and healthcare professionals, the announcement helps explain why some companion apps may appear in a medicine’s official labeling while others do not. Its primary audience is drug companies and their technology partners, rather than people seeking instructions for using a particular medicine.
What the guidance on prescription drug apps covers
According to the FDA’s announcement of the final guidance, the framework answers three main questions: when app content is considered FDA-required labeling rather than promotional labeling, when an app should be referenced in a drug’s prescribing information, and what companies should submit when distributing app content to users.
These are related but distinct issues. Whether an app belongs in official prescribing information concerns its role alongside the medicine. How the content displayed within that app is classified concerns the information delivered to users. The announcement addresses both, rather than treating every companion app and every piece of app content the same way.
Two categories of companion software
Apps connected to a medical device
The FDA says apps connected to a medical device, such as software paired with an asthma inhaler, generally should be described in the drug’s official prescribing information. The agency ties that recommendation to the central role the software plays in how the medicine is used.
The word “generally” matters: the announcement describes a regulatory approach, not a product-by-product list. It does not name individual apps or provide instructions for operating a connected inhaler or other device.
Standalone apps
The second category includes standalone tools such as symptom trackers, dose reminders, and health coaching apps. Under the guidance, these apps should appear in prescribing information if the company can show that the software is essential for safe and effective use or can demonstrate a meaningful clinical benefit.
That distinction is important when interpreting an app’s purpose. A reminder or tracking feature is an example of standalone software; the announcement does not establish that every such feature provides a meaningful clinical benefit. Instead, it describes the circumstances under which a company’s app should be included in official labeling.
How FDA will treat content shown to users
In most cases, the FDA says content displayed by a companion app will be treated as promotional material, consistent with the agency’s approach to other drug advertising. This is separate from the question of whether the app itself should be referenced in prescribing information.
The framework therefore does not make all information displayed in a companion app part of a medicine’s official prescribing label. Understanding that distinction can help readers interpret what the FDA’s announcement does—and does not—say about these tools.
What patients and healthcare professionals can take away
The announcement is useful for understanding the oversight of software supplied alongside prescription medicines. The FDA says its goal is to reduce uncertainty for developers and manufacturers while preserving safety and effectiveness standards and supporting accurate, evidence-based communication.
It does not provide a treatment plan, recommend a particular app, or explain how an individual should respond to symptoms or app messages. Questions about whether a specific companion app is appropriate for someone’s prescribed treatment, or how its information relates to their care, require discussion with a healthcare professional rather than an answer from this regulatory announcement.
Frequently Asked Questions
Does every companion app belong in a drug’s prescribing information?
No. Device-connected apps generally should be described there. Standalone apps should be included when the company demonstrates that they are essential for safe and effective use or provide a meaningful clinical benefit.
Is everything displayed in an app FDA-required labeling?
No. The FDA says most content displayed by companion apps will be treated as promotional material, consistent with other drug advertising.
Does this announcement recommend an app for my medicine?
No. It explains a regulatory framework, not individual app choices. A healthcare professional can address questions about a specific app’s role in your care.
